Search enhanced by Google
Michelle L. Apperson, M.D., Ph.D.
Clinical Professor
Director, UC Davis Multiple Sclerosis Program
To see if Michelle L. Apperson is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).
Locations and Contact
UC Davis Midtown Ambulatory Care Center
Midtown Neurology Clinic
3160 Folsom Blvd
Sacramento, CA 95816
Phone: 916-734-3588
Clinical Interests
Dr. Apperson's clinical interests include: General Neurology, Multiple Sclerosis, and Neuromyelitis Optica.
Research/Academic Interests
Dr. Apperson's research interests include clinical trials of novel multiple sclerosis treatments and identification of multiple sclerosis biomarkers.
Dr. Apperson is conducting genetic, genomic and other biochemical blood profiling to further elucidate the relationship between genetics and environmental factors in the autoimmune etiology of multiple sclerosis.
Division
Neurology
Undergraduate School
B.A., UC San Diego, San Diego CA 1988
Medical School
M.D., University of Hawaii, John A. Burns School of Medicine, Manoa HI 2001
Other School
Ph.D., Philosophy, California Institute of Technology, Pasadena CA 1996
Internship
Internal Medicine, University of Hawaii at Manoa, Honolulu HI 2001-2002
Residency
Neurology, UC Davis Medical Center, Sacramento CA 2002-2005
Fellowship
Neurology/Multiple Sclerosis, UC Davis Medical Center, Sacramento CA 2005-2008
UC Davis Neurology Senior Resident Appreciation Award, 2010, 2015
Sylvia Lawry Physician Fellow of the National Multiple Sclerosis Society, 2006-2008,
Chief Residency at UC Davis Neurology Residency Program, 2004
Yuan O, Lin C, Wagner J, Archard JA, Deng P, Halmai J, Bauer G, Fink KD, Fury B, Perotti NH, Walker JE, Pollock K, Apperson M, Butters J, Belafsky P, Farwell DG, Kuhn M, Nolta J, Anderson JD. Exosomes Derived from Human Primed Mesenchymal Stem Cells Induce Mitosis and Potentiate Growth Factor Secretion. Stem Cells Dev. 2019 Mar 15;28(6):398-409. doi:10.1089/scd.2018.0200. Epub 2019 Feb 26. PMID:30638129.
Fox RJ, Coffey CS, Conwit R, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Naismith RT, Ashokkumar A, Barnes J, Ecklund D, Klingner E, Koepp M, Long JD, Natarajan S, Thornell B, Yankey J, Bermel RA, Debbins JP, Huang X, Jagodnik P, Lowe MJ, Nakamura K, Narayanan S, Sakaie KE, Thoomukuntla B, Zhou X, Krieger S, Alvarez E, Apperson M, Bashir K, Cohen BA, Coyle PK, Delgado S, Dewitt LD, Flores A, Giesser BS, Goldman MD, Jubelt B, Lava N, Lynch SG, Moses H, Ontaneda D, Perumal JS, Racke M, Repovic P, Riley CS, Severson C, Shinnar S, Suski V, Weinstock-Guttman B, Yadav V, Zabeti A; NN102/SPRINT-MS Trial Investigators. Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis. N Engl J Med. 2018 Aug 30;379(9):846-855. doi:10.1056/NEJMoa1803583. PMID:30157388.
Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F; EXPAND Clinical Investigators. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018 Mar 31;391(10127):1263-1273. doi:10.1016/S0140-6736(18)30475-6. Epub 2018 Mar 23. Erratum in: Lancet. 2018 Nov 17;392(10160):2170. PMID:29576505.
Derlet A, Agius M, Apperson ML. Symptomatic Thrombocytopenia After One Dose of Alemtuzumab With Successful Rechallenge. Neurology. 2017 Apr 27;88(16 Supplement) P5.400.
Miller DH, Fox RJ, Phillips JT, Hutchinson M, Havrdova E, Kita M, Wheeler-Kingshott CA, Tozer DJ, MacManus DG, Yousry TA, Goodsell M, Yang M, Zhang R, Viglietta V, Dawson KT; CONFIRM study investigators. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology. 2015 Mar 17;84(11):1145-52. doi:10.1212/WNL.0000000000001360. Epub 2015 Feb 13. PMID:25681448.
Parish MB, Apperson M, Yellowlees PM. Engaging U.S. veterans with PTSD in online therapy. Psychiatr Serv. 2014 May 1;65(5):697. doi:10.1176/appi.ps.650501. PMID:24788736.
Apperson ML, Tian Y, Stamova B, Ander BP, Jickling GC, Agius MA, Sharp FR. Genome wide differences of gene expression associated with HLA-DRB1 genotype in multiple sclerosis: a pilot study. J Neuroimmunol. 2013 Apr 15;257(1-2):90-6. doi:10.1016/j.jneuroim.2013.02.004. Epub 2013 Mar 9. PMID:23477965.
Dias RA, Hardin KA, Rose H, Agius MA, Apperson ML, Brass SD. Sleepiness, fatigue, and risk of obstructive sleep apnea using the STOP-BANG questionnaire in multiple sclerosis: a pilot study. Sleep Breath. 2012 Dec;16(4):1255-65. doi:10.1007/s11325-011-0642-6. Epub 2012 Jan 21. PMID:22270686.
Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT; CONFIRM Study Investigators. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012 Sep 20;367(12):1087-97. doi:10.1056/NEJMoa1206328. Erratum in: N Engl J Med. 2012 Oct 25;367(17):1673. PMID:22992072.
Magley J, Towner D, Taché V, Apperson ML. Pregnancy outcome in anti-N-methyl-D-aspartate receptor encephalitis. Obstet Gynecol. 2012 Aug;120(2 Pt 2):480-483. doi:10.1097/AOG.0b013e31825935d4. PMID:22825272.